Sage Therapeutics to Present at American Academy of Neurology 2017 Annual Meeting
April 19 2017 - 7:00AM
Business Wire
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage
biopharmaceutical company developing novel medicines to treat
life-altering central nervous system (CNS) disorders, today
announced upcoming presentations for brexanolone (SAGE-547) and
SAGE-217 at the American Academy of Neurology (AAN) 2017 Annual
Meeting, taking place April 22-28, 2017 in Boston, Mass.
Below is the schedule for the presentations:
Date: April 25, 2017Poster Presentation Time: 8:30
a.m.-7:00 p.m. ETLocation: Poster Hall, Neighborhood
APoster Number: P3.008Title: The pharmacokinetics of
SAGE-217 in Phase 1 SAD and MAD studies
Date: April 25, 2017Poster Presentation Time: 8:30
a.m.-7:00 p.m. ETLocation: Poster Hall, Neighborhood
APoster Number: P3.009Title: Next-generation
neuroactive steroid SAGE-217 in a multiple-ascending dose study
Date: April 25, 2017Poster Presentation Time: 8:30
a.m.-7:00 p.m. ETLocation: Poster Hall, Neighborhood
GPoster Number: P3.224Title: Evaluation of the costs,
length of stay, and mortality associated with super-refractory
status epilepticus in Germany
Date: April 27, 2017Poster Presentation Time: 8:30
a.m.-7:00 p.m. ETLocation: Poster Hall, Neighborhood
APoster Number: P5.021Title: Preclinical
characterization of SAGE-217 in a rodent model of oral
dyskinesia
Date: April 28, 2017Poster Presentation Time: 8:30
a.m.-5:30 p.m. ETLocation: Poster Hall, Neighborhood
APoster Number: P6.017Title: Next-generation
neuroactive steroid SAGE-217 in a single-ascending dose study
Date: April 28, 2017Poster Presentation Time: 8:30
a.m.-5:30 p.m. ETLocation: Poster Hall, Neighborhood
BPoster Number: P6.068Title: Preclinical pharmacology
and pharmacodynamic interactions of SAGE-547: Relevance to
super-refractory status epilepticus (SRSE)
Date: April 28, 2017Poster Presentation Time: 8:30
a.m.-5:30 p.m. ETLocation: Poster Hall, Neighborhood
GPoster Number: P6.234Title: Hemodynamic properties
of SAGE-547 in patients with super-refractory status epilepticus:
results from a Phase 1/2 clinical trial
Date: April 28, 2017Poster Presentation Time: 8:30
a.m.-5:30 p.m. ETLocation: Poster Hall, Neighborhood
GPoster Number: P6.241Title: Pharmacokinetics of
SAGE-547 in patients with super-refractory status epilepticus
About Sage TherapeuticsSage Therapeutics is a
clinical-stage biopharmaceutical company committed to developing
novel medicines to transform the lives of patients with
life-altering central nervous system (CNS) disorders. Sage has a
portfolio of novel product candidates targeting critical CNS
receptor systems, GABA and NMDA. Sage's lead program, brexanolone
(SAGE-547), is in Phase 3 clinical development for super-refractory
status epilepticus, a rare and severe seizure disorder, and for
postpartum depression. Sage is developing its next generation
modulators, including SAGE-217 and SAGE-718, in various CNS
disorders. For more information, please visit www.sagerx.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170419005287/en/
Investor Contact:Sage TherapeuticsPaul Cox,
617-299-8377paul.cox@sagerx.comorMedia Contact:Suda
Communications LLCMaureen L. Suda,
585-387-9248maureen.suda@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Apr 2023 to Apr 2024